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Gastrinoma is the most common neuroendocrine 
tumor in patients with multiple endocrine neopla-
sia type 1 (MEN 1)6,10,11).  Gastrinomas in a patient 
with MEN 1 tend to be multiple and too small for 
imaging methods to show them, making the local-
ization and diagnosis of these microgastrinomas 
difficult preoperatively.  Endoscopic ultrasonogra-
phy (EUS) is a useful method for showing and di-
agnosing submucosal microgastrinomas, but in a 
case of severe stenosis caused by recurrent ulcers, 
it was impossible for EUS to pass through the ste-
nosis and show the microgastrinomas.  Some have 
recommended the use of the selective arterial calci-
um injection (SACI) test as a valid diagnostic 
method for the localization of these invisible micro-
gastrinomas preoperatively4,8,12).  We report a rare 
case of multiple invisible duodenal microgastrino-
mas and pancreatic neuroendocrine tumors in a 
patient with MEN 1 with severe duodenal stenosis 
diagnosed preoperatively by using the SACI test. 
CASE PRESENTATION
A 50-year-old man was admitted to our hospital 
with recurrent duodenal ulcers causing epigastric 
pain, nausea and vomiting.  He had been treated 
with proton pump inhibitors for duodenal ulcers 
for 2 years.  Despite continuous proton pump 
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ABSTRACT
The localization and diagnosis of microgastrinomas in a patient with multiple endocrine neo-
plasia type 1 is difficult preoperatively.  The selective arterial calcium injection (SACI) test is a 
valid diagnostic method for the preoperative diagnosis of these invisible microgastrinomas.  We 
report a rare case of multiple invisible duodenal microgastrinomas with severe duodenal steno-
sis diagnosed preoperatively by using the SACI test.  A 50-year-old man was admitted to our 
hospital with recurrent duodenal ulcers.  His serum gastrin level was elevated to 730 pg/ml.  It 
was impossible for gastrointestinal endoscopy to pass through to visualize the inferior part of 
the duodenum, because recurrent duodenal ulcers had resulted in severe duodenal stenosis.  The 
duodenal stenosis also prevented additional endoscopic examinations such as endoscopic ultraso-
nography.  Computed tomography did not show any tumors in the duodenum and pancreas.  The 
SACI test provided the evidence for a gastrinoma in the vascular territory of the inferior pancre-
atic-duodenal artery.  We diagnosed a gastrinoma in the peri- ampullary lesion, so we performed 
Subtotal Stomach-Preserving Pancreatico- duodenectomy with regional lymphadenectomy.  His-
topathological findings showed multiple duodenal gastrinomas with lymph node metastasis and 
nonfunctioning pancreatic neuroendocrine tumors.  Twenty months after surgery, the patient is 
alive with no evidence of recurrence and a normal gastrin level.  In conclusion, the SACI test 
can enhance the accuracy of preoperative localization and diagnosis of invisible microgastrino-
mas, especially in the setting of severe duodenal stenosis.
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parathyroid adenoma, but brain magnetic reso-
nance imaging (MRI) showed a normal pituitary 
gland.
We diagnosed a gastrinoma in the peri-ampulla-
ry lesion with MEN 1, so we performed Subtotal 
Stomach-Preserving Pancreaticoduodenectomy 
(SSPPD) with regional lymphadenectomy (Fig. 3).
Histopathological findings showed 4 small neuroen-
docrine tumors sized within 3 mm in the duodenum 
(DNETs) (Fig. 4a-c), 4 small neuroen docrine tumors 
sized within 3mm in the head of pancreas (PNETs) 
(Fig. 5a-c) and 1 lymph node metastasis in the pos-
terior part of the head of pancreas (Fig. 6a-b).  Im-
munohistochemical examination found that the 
DNETs and the lymph node metastasis were posi-
tive for chromogranin A (CgA), synaptophysin and 
gastrin.  On the other hand, the PNETs were posi-
tive for CgA and synaptophysin, but negative for 
gastrin.  The Ki-67 labeling index of the DNETs 
and the metastatic lymph node were about 10%, 
and that of the PNETs was < 2%.  By WHO classi-
fication 2010, the DNETs were NET G2, and the 
PNETs were NET G1.  The patient was diagnosed 
with multiple duodenal gastrinomas with lymph 
node metastasis and nonfunctioning PNETs with 
MEN 1.
In the postoperative course, the pancreatic fistula 
as a complication was treated with conservative 
measures.  He was discharged from the hospital on 
the 51st postoperative day.  Ten months after the 
surgery, parathyroidectomy was performed for the 
suspected parathyroid adenoma.  Histopathological 
findings showed the parathyroid adenoma.  Now 
twenty months after the first surgery, SSPPD, the 
patient is alive with a normal gastrin level and 
without any evidence of recurrence.
inhibitor treatment, his abdominal symptoms did 
not improve.  There was no other past medical 
history except for the duodenal ulcers.  His father 
had died of an unspecified pancreatic tumor. 
Laboratory tests showed elevated levels of serum 
calcium (12.8 mg/dl), gastrin (730 pg/ml), and 
parathyroid hormone (2,000 pg/ml), but prolactin 
was normal (18.3 ng/ml).
Gastrointestinal endoscopy (GIS) showed a giant 
ulcer filling one third of the lumen of the duodenum. 
It was impossible to pass the en do scope through this 
lesion to view the inferior part, because recurrent 
duodenal ulcers had resulted in severe duodenal ste-
nosis.  In addition, the duodenal stenosis prevented 
additional endoscopic examinations such as EUS 
from showing submucosal tumors such as gastri-
nomas and obtaining specimens by fine-needle as-
piration of the tumors.  The tissue biopsied from 
these ulcerative lesions was negative for duodenal 
carcinoma.  Contrast-enhanced computed tomog-
raphy (CT) showed duodenal wall thickening and 
edema of the descending part of the duodenum, 
but did not show tumors in the duodenum and 
pancreas (Fig. 1a).  Only one lymph node sized 
within 16 mm in diameter in the posterior part of 
the head of pancreas was enhanced (Fig. 1b).  An-
giography and the SACI test were performed to 
identify the arterial supply of the gastrinoma. 
The gastroduodenal artery, inferior pancreatic- 
duodenal artery (IPDA), proper hepatic artery and 
splenic artery were selectively catheterized.  This 
test provided the evidence for a gastrinoma in the 
vascular territory of the IPDA, the peri-ampullary 
lesion, and the absence of hepatic metastases (Fig. 
2).  In addition, parathyroid and pituitary gland 
evaluation were conducted to diagnose the MEN 1. 
Thyroid ultrasonography showed a suspected 
a b
Fig. 1. Computed tomography.
(a) Arrow indicates duodenal wall thickening and edema.
(b) Arrow indicates enhanced lymph node sized within 16 mm in diameter in the posterior part of the head 
of pancreas.
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Fig. 2. Results of the SACI test.
The gastroduodenal artery, inferior pancreatic-
duodenal artery (IPDA), proper hepatic artery and 
splenic artery were selected.  Injection of calcium into 
IPDA resulted in a sharp rise in this artery gastrin 
levels (before: 1400 pg/ml, after 60s: 3600 pg/ml).
Fig. 3. We performed Subtotal Stomach-Preserving 
Pancreaticoduodenectomy with regional lymphade-
nectomy.
Histopathological findings of the resected specimen.
a b
c
Fig. 4. Small duodenal neuroendocrine tumors.
(a) H.E staining. Arrow indicates one of 4 small submucosal tumors sized within 3 mm.
(b) Immunohistochemical staining for CgA.  The tumors were positive for CgA.  They were duodenal neuroendocrine 
tumors (DNETs).
(c) Immunohistochemical staining for gastrin.  The DNETs were positive for gastrin.  They were diagnosed as 
duodenal gastrinomas.
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contrast-enhanced CT, and MRI are used for preop-
erative diagnosis of microgastrinomas, but these 
imaging studies may fail to show them.  EUS is 
also a useful method for detecting submucosal 
small tumors as small as 2-3 mm in diameter1) but, 
in our case, severe duodenal stenosis prevented 
careful examination with any standard modality. 
The SACI test was the only valid method for local-
ization and diagnosis of the invisible microgastrino-
DISCUSSION
The SACI test is a highly accurate and safe 
method for the preoperative localization and diag-
nosis of gastrinomas with MEN 1 in the duodenum 
or/and pancreas and is especially helpful in a case 
of duodenal stenosis.  More than half of duodenal 
gastrinomas with MEN 1 tend to be smaller than 1 
cm in diameter3,12).  Imaging studies such as GIS, 
a b
c
Fig. 5. Small pancreatic neuroendocrine tumors.
(a) H.E staining. Arrow indicates one of 4 small 
pancreatic tumors sized within 3 mm.
(b) Immunohistochemical staining for CgA. 
The tumors were positive for CgA.  They were 
pancreatic neuroendocrine tumors (PNETs).
(c) Immunohistochemical staining for gastrin. 
The PNETs were negative for gastrin.  They 
were diagnosed as nonfunctioning PNETs.
a b
Fig. 6. The metastatic lymph node.
(a) Immunohistochemical staining for CgA.  The lymph node was positive for CgA.  It was metastatic lymph node of 
NETs.
(b) Immunohistochemical staining for gastrin.  The metastatic lymph node was positive for gastrin.  It was diagnosed 
as the metastatic lymph node of duodenal gastrinomas.
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mas.
The treatment strategy for gastrinomas with 
MEN 1 has been controversial.  We recommend 
early and aggressive surgical resection of gastri-
nomas, because recently published articles suggest 
that this improves survival rates and the long 
term biomedical cure of gastrinomas as well as de-
creasing the rate of hepatic metastases2,5,7,9).  The 
preoperative diagnosis in our case was invisible 
gastrinomas in the peri-ampullary lesion, so we 
selected “total” duodenectomy rather than “par-
tial” duodenectomy.  In addition, any regional 
lymph nodes around the head of the pancreas and 
hepatic artery should be dissected, because duode-
nal gastrinomas reportedly metastasize to region-
al lymph nodes independent of size7,8).  In our case, 
the preoperative CT showed one highly enhanced 
lymph node sized within 16 mm in diameter in the 
posterior part of the head of the pancreas.  Pancre-
as preserving total duodenectomy to save the head 
of the pancreas offered a less invasive surgery 
compared with SSPPD, but this procedure did not 
allow for regional lymph node dissection and the 
resection of microgastrinomas in the head of the 
pancreas.  With total duodenectomy, regional 
lymph node dissection and the possibility of micro-
gastrinomas in the head of pancreas, we per-
formed SSPPD.  As a result, pathological findings 
showed that one highly enhanced metastatic 
lymph node was larger than the primary duodenal 
microgastrinomas, so it was possible for the meta-
static lymph node to secrete more gastrin than the 
duodenal microgastrinomas and to be fed from 
IPDA, identified by the SACI test as the arterial 
supply of the gastrinoma.  Proper preoperative di-
agnosis by the SACI test and early and aggressive 
surgical resection contributed to curative R0 re-
section and recurrence-free survival.
CONCLUSION
The SACI test can enhance the accuracy of 
preoperative localization and diagnosis of invisible 
microgastrinomas, especially in the setting of 
severe duodenal stenosis.
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